Table 2 Patient disposition and treatment exposure (safety population)
Bortezomib-rituximab (N=102) | Rituximab (N=98) | |
|---|---|---|
Median number of cycles, n (range) | 5 (1–5) | 5 (1–5) |
Median treatment duration, weeks (range) | 25 (5–33) | 25 (5–27) |
Patients completing all 5 cycles, n (%) | 65 (64) | 52 (53) |
Patients discontinuing prior to completing 5 cycles, n (%), due to: | 37 (36) | 46 (47) |
Disease progression | 26 (25) | 38 (39) |
AEs | 8 (8) | 2 (2) |
Treatment-related | 6 (6) | 0 |
Death | 1 (1) | 1 (1) |
Patient choice | 2 (2) | 4 (4) |
Other reasons | 0 | 1 (1) |
Mean rituximab relative dose intensity, % | 98 | 96 |
Mean bortezomib relative dose intensity, % | 90 | NA |